image layout frameless
Anti-IgLON5 disease
are Rituximab (22%) and Cyclophosphamide (12%), Azathioprine and
Mycophenolat
Mofetil
. Sudden death is the most common outcome in nearly 34% of patients...
11 KB (1,094 words) - 03:35, 18 June 2024